ASH 2014: BCL-2 Pathway in CLL (chronic lymphocytic leukemia) In the second part of my interview from ASH 2014 with Dr. Jeff Sharman, we learn more basic biology of... September 1, 20152014 ConferencesBy Todd Dennison
ASH 2014: Dr. Sharman on Cracking the Biology of CLL (Chronic Lymphocytic Leukemia) In the first of a two-part interview recorded at the 2014 American Society of Hematology annual meeting with Dr. Jeff... August 27, 20152014 ConferencesBy Todd Dennison
ESH 2014: Prof. Hallek Discusses Clinical Trial Goals in CLL In Part 2 of our interview from ESH (European School of Hematology) 2014, Professor Michael Hallek who heads up the German... June 30, 20152014 ConferencesBy Todd Dennison
ESH 2014: Prof. Hallek Discusses Trials to Achieve Long-Term Disease Control of CLL Professor Michael Hallek of the German CLL Study Group spent some time with me at the 2014 European School of... June 23, 20152014 ConferencesBy Todd Dennison
ASH 2014: Dr. Adrian Wiestner Reviews Data on Novel Oral Therapies for CLL In an interview with Dr. Adrian Weistner from the National Institutes of Health in Bethesda, MD, we discussed the latest data on... May 25, 20152014 Conferences, NewsBy Todd Dennison
ESH 2014: Dr. Jennifer Brown Discusses Second Generation BTK Inhibitors in CLL At the 2014 European School of Hematology (ESH) meeting in Greece, Dr. Jennifer Brown gave a lecture on second-generation Bruton... May 22, 20152014 ConferencesBy Todd Dennison
ASH 2014: Dr. Jan Burger on Ibrutinib and Rituximab in CLL At the 2014 American Society of Hematology meeting, Dr. Jan Burger from the MD Anderson Cancer Center presented some of the findings... May 20, 20152014 ConferencesBy Todd Dennison
ASH 2014: Dr. Jan Burger on Ibrutinib Resistance in CLL Dr. Jan Burger from the MD Anderson Cancer Center spoke to me about his research on ibrutinib resistance in chronic... May 18, 20152014 ConferencesBy Todd Dennison
ASH 2014: Prof. Hillmen Describes Adaptive Clinical Trial Design in CLL At the 2014 American Society of Hematology annual meeting in San Francisco, CA, Professor Peter Hillmen out of Leeds, England describes... May 15, 20152014 ConferencesBy clladm1n
ASH 2014: Prof. Hillmen On Measuring Success with Targeted Therapies in CLL At the 2014 American Society of Hematology annual meeting in San Francisco, Professor Peter Hillmen from the University of Leeds explains the... May 13, 20152014 ConferencesBy clladm1n
